Sign Out
Traceability: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Hypersensitivity: Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event following the administration of the vaccine.
Intercurrent illness: Vaccination should be postponed in patients with acute febrile illness until the fever is resolved.
Immunodeficiency: Antibody response in patients with endogenous or iatrogenic immunosuppression may be insufficient to prevent influenza.
Thrombocytopenia and coagulation disorders: As with all injectable vaccines, Flublok must be administered with caution to individuals with thrombocytopaenia or a bleeding disorder since bleeding may occur following an intramuscular administration to these subjects.
Syncope: Syncope can occur following or even before any vaccination as a psychogenic response to the needle injection. This can be accompanied by several neurological signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during recovery. Procedures should be in place to prevent falling and injury and to manage syncope.
Protection: As with any vaccine, vaccination with Flublok may not protect all vaccinees.
Sodium content: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say is essentially "sodium free".
Effects on ability to drive and use machines: Flublok has no or negligible influence on the ability to drive and use machines.
